These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8845704)

  • 1. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of Tacrine and the measurement of outcomes of Alzheimer's disease.
    Int J Technol Assess Health Care; 1998; 14(2):398-9. PubMed ID: 9678977
    [No Abstract]   [Full Text] [Related]  

  • 5. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrine: a second look. An outdated drug to be discarded.
    Prescrire Int; 1999 Feb; 8(39):16-8. PubMed ID: 10557569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
    Kaufer DI; Cummings JL; Christine D
    J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):1-6. PubMed ID: 8679057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.
    Kaufer D; Cummings JL; Christine D
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):55-63. PubMed ID: 9547467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic results: tacrine].
    Ventura M; Sternon J
    Rev Med Brux; 1997 Dec; 18(6):394-7. PubMed ID: 9481161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognition-enhancing drugs in dementia: a guide to the near future.
    van Reekum R; Black SE; Conn D; Clarke D
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():35S-50S. PubMed ID: 9220128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
    Conway EL
    Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.
    Ahlin A; Junthé T; Hassan M; Nybäck H
    Int Psychogeriatr; 1995; 7(1):75-83. PubMed ID: 7579023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tacrine against Alzheimer disease? Still uncertain for which patients may the treatment be beneficial].
    Wallin A
    Lakartidningen; 1996 Jan; 93(1-2):22-4. PubMed ID: 8544526
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of repeated measurements with dropouts among Alzheimer's disease patients using summary measures and meta-analysis.
    Talwalker S
    J Biopharm Stat; 1996 Mar; 6(1):49-58. PubMed ID: 8838778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.